Fagron (FAGR) Stock Overview
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
FAGR Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Fagron NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €24.70 |
| 52 Week High | €25.30 |
| 52 Week Low | €19.24 |
| Beta | 0.38 |
| 1 Month Change | 3.35% |
| 3 Month Change | 11.26% |
| 1 Year Change | 12.53% |
| 3 Year Change | 53.99% |
| 5 Year Change | 24.43% |
| Change since IPO | 145.28% |
Recent News & Updates
Narrative Update • Jun 03
FAGR: Dividend Uptick And Higher P E Profile Will Support Future Upside
Analysts have raised their price target on Fagron to €29.00 from €28.00, citing updated views that refine assumptions related to growth, profitability and the stock’s future P/E profile. What's in the News Fagron approved a gross dividend of €0.40 per share at its Annual and Extraordinary General Meeting of Shareholders held on 11 May 2026, with ex-dividend on 18 May 2026, record date on 19 May 2026, and payment on 20 May 2026.Narrative Update • May 15
FAGR: Higher Dividend And Recalibrated Earnings Multiple Will Support Future Upside
Narrative Update on Fagron The analyst price target for Fagron has been lifted from €28 to €29, with analysts pointing to their updated assumptions on the discount rate and forward P/E as key drivers of the €1 increase. Analyst Commentary Bullish analysts lifting the price target to €29 focus on valuation inputs rather than a big shift in the core story.Narrative Update • Apr 25
FAGR: Higher Dividend And Reinforced Outlook Will Support Future Upside
Analysts have raised their price target on Fagron to €29 from €28, reflecting updated assumptions that leave fair value, discount rate, revenue growth, profit margin and future P/E broadly unchanged overall. Analyst Commentary Analysts keeping their fair value framework broadly unchanged while lifting the price target to €29 suggests a fine tuning of expectations rather than a major shift in view.Recent updates
Narrative Update • Jun 03
FAGR: Dividend Uptick And Higher P E Profile Will Support Future Upside
Analysts have raised their price target on Fagron to €29.00 from €28.00, citing updated views that refine assumptions related to growth, profitability and the stock’s future P/E profile. What's in the News Fagron approved a gross dividend of €0.40 per share at its Annual and Extraordinary General Meeting of Shareholders held on 11 May 2026, with ex-dividend on 18 May 2026, record date on 19 May 2026, and payment on 20 May 2026.Narrative Update • May 15
FAGR: Higher Dividend And Recalibrated Earnings Multiple Will Support Future Upside
Narrative Update on Fagron The analyst price target for Fagron has been lifted from €28 to €29, with analysts pointing to their updated assumptions on the discount rate and forward P/E as key drivers of the €1 increase. Analyst Commentary Bullish analysts lifting the price target to €29 focus on valuation inputs rather than a big shift in the core story.Narrative Update • Apr 25
FAGR: Higher Dividend And Reinforced Outlook Will Support Future Upside
Analysts have raised their price target on Fagron to €29 from €28, reflecting updated assumptions that leave fair value, discount rate, revenue growth, profit margin and future P/E broadly unchanged overall. Analyst Commentary Analysts keeping their fair value framework broadly unchanged while lifting the price target to €29 suggests a fine tuning of expectations rather than a major shift in view.Narrative Update • Apr 10
FAGR: Higher Dividend And Refined Earnings Outlook Will Support Future Upside
Analysts have raised their price target on Fagron by €1 to €29, reflecting updated views on the company after recent research. Analyst Commentary Analysts have adjusted their view on Fagron with a new price target of €29, which is €1 above the prior figure of €28.Narrative Update • Mar 26
FAGR: Higher Payout And Updated Earnings Assumptions Will Support Future Upside
Analysts have lifted the Fagron price target to €28.25 from €26.92, citing updated assumptions on revenue growth, profit margins and future P/E multiples in line with recent Street research pointing to a €29 target. Analyst Commentary Bullish analysts lifting their targets toward €29 are effectively signalling more confidence in the assumptions behind Fagron's revenue growth, margin profile and the P/E level the market might be willing to pay for the shares.Narrative Update • Mar 12
FAGR: Coast To Coast Licensing And Dividend Uplift Will Support Future Upside
Narrative update on Fagron The analyst price target for Fagron has moved from €28 to €29, with analysts pointing to updated assumptions on revenue growth, profit margins, and future P/E as key reasons for the change. Analyst Commentary Bullish analysts nudging their price target to €29 are signaling that, based on their assumptions, the current share price still leaves some room for upside if Fagron delivers on execution.Narrative Update • Feb 26
FAGR: Coast To Coast Licensing And Dividend Growth Will Support Future Upside
Analysts have adjusted their price target on Fagron slightly higher from €26.08 to €26.75. This reflects updated assumptions around modestly different revenue growth, profit margin and future P/E expectations.Narrative Update • Feb 11
FAGR: Coast To Coast Licensing Platform Will Support A Stronger Future Position
Analysts have nudged their price expectations for Fagron higher, with the average fair value estimate moving from €24.84 to about €26.08 as they revisit assumptions around revenue growth, profit margins and future P/E levels. What's in the News Fagron obtained a license for its new Anazao Health facility in Tampa from the California State Board of Pharmacy, allowing shipment of patient specific compounded medications to California and supporting a coast to coast platform for its Health and Wellness business (Key Developments).Analysis Article • Dec 20
Fagron NV's (EBR:FAGR) Intrinsic Value Is Potentially 76% Above Its Share Price
Key Insights The projected fair value for Fagron is €37.41 based on 2 Stage Free Cash Flow to Equity Fagron's €21.30...Analysis Article • Oct 29
Fagron NV's (EBR:FAGR) Popularity With Investors Is Under Threat From Overpricing
Fagron NV's ( EBR:FAGR ) price-to-earnings (or "P/E") ratio of 17.5x might make it look like a sell right now compared...Analysis Article • Apr 08
These 4 Measures Indicate That Fagron (EBR:FAGR) Is Using Debt Reasonably Well
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
New Narrative • Feb 23
New Compounding Services Strategy Will Drive Customer Acquisition In North America
Strategic acquisitions and improved commercial strategies are enhancing Fagron's market position, driving revenue growth, and expanding the product portfolio in key regions.Analysis Article • Dec 24
Return Trends At Fagron (EBR:FAGR) Aren't Appealing
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Analysis Article • Oct 07
Risks To Shareholder Returns Are Elevated At These Prices For Fagron NV (EBR:FAGR)
Fagron NV's ( EBR:FAGR ) price-to-earnings (or "P/E") ratio of 16.8x might make it look like a sell right now compared...Analysis Article • May 07
Fagron NV's (EBR:FAGR) CEO Will Probably Find It Hard To See A Huge Raise This Year
Key Insights Fagron will host its Annual General Meeting on 13th of May Total pay for CEO Rafael Padilla includes...Analysis Article • Apr 17
The Returns At Fagron (EBR:FAGR) Aren't Growing
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analysis Article • Mar 15
Is Fagron (EBR:FAGR) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Feb 18
Earnings Tell The Story For Fagron NV (EBR:FAGR)
Fagron NV's ( EBR:FAGR ) price-to-earnings (or "P/E") ratio of 18.4x might make it look like a sell right now compared...Analysis Article • Aug 11
Fagron (EBR:FAGR) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analysis Article • Jun 10
Be Wary Of Fagron (EBR:FAGR) And Its Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...Analysis Article • May 12
Fagron (EBR:FAGR) Has Announced That It Will Be Increasing Its Dividend To €0.175
Fagron NV ( EBR:FAGR ) will increase its dividend from last year's comparable payment on the 17th of May to €0.175. The...Analysis Article • Apr 20
An Intrinsic Calculation For Fagron NV (EBR:FAGR) Suggests It's 30% Undervalued
Key Insights The projected fair value for Fagron is €24.87 based on 2 Stage Free Cash Flow to Equity Fagron's €17.46...Analysis Article • Apr 02
Is Fagron (EBR:FAGR) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Oct 14
Here's Why Fagron (EBR:FAGR) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysis Article • Jun 04
Return Trends At Fagron (EBR:FAGR) Aren't Appealing
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analysis Article • May 13
Fagron (EBR:FAGR) Is Paying Out A Larger Dividend Than Last Year
Fagron NV ( EBR:FAGR ) will increase its dividend on the 18th of May to €0.14. Despite this raise, the dividend yield...Analysis Article • Apr 13
Is Fagron (EBR:FAGR) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Feb 16
Slowing Rates Of Return At Fagron (EBR:FAGR) Leave Little Room For Excitement
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Typically, we'll want...Analysis Article • Nov 18
Fagron (EBR:FAGR) Has A Pretty Healthy Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysis Article • Sep 25
Fagron (EBR:FAGR) Is Experiencing Growth In Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'd want to...Shareholder Returns
| FAGR | BE Healthcare | BE Market | |
|---|---|---|---|
| 7D | 5.6% | 1.9% | 0.7% |
| 1Y | 12.5% | -11.5% | 19.5% |
Return vs Industry: FAGR exceeded the Belgian Healthcare industry which returned -11.5% over the past year.
Return vs Market: FAGR underperformed the Belgian Market which returned 19.5% over the past year.
Price Volatility
| FAGR volatility | |
|---|---|
| FAGR Average Weekly Movement | 2.8% |
| Healthcare Industry Average Movement | 5.1% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in BE Market | 7.8% |
| 10% least volatile stocks in BE Market | 2.6% |
Stable Share Price: FAGR has not had significant price volatility in the past 3 months compared to the Belgian market.
Volatility Over Time: FAGR's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 4,193 | Rafael Padilla | www.fagron.com |
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort; and Cleoderm, a topical cream used for the compounding of personalized dermatological treatments.
Fagron NV Fundamentals Summary
| FAGR fundamental statistics | |
|---|---|
| Market cap | €1.79b |
| Earnings (TTM) | €91.02m |
| Revenue (TTM) | €952.17m |
19.9x
P/E Ratio1.9x
P/S RatioIs FAGR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FAGR income statement (TTM) | |
|---|---|
| Revenue | €952.17m |
| Cost of Revenue | €520.16m |
| Gross Profit | €432.01m |
| Other Expenses | €340.99m |
| Earnings | €91.02m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Jul 30, 2026
| Earnings per share (EPS) | 1.24 |
| Gross Margin | 45.37% |
| Net Profit Margin | 9.56% |
| Debt/Equity Ratio | 74.3% |
How did FAGR perform over the long term?
See historical performance and comparisonDividends
1.6%
Current Dividend Yield32%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/10 17:56 |
| End of Day Share Price | 2026/06/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fagron NV is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Beatrice Fairbairn | Berenberg |
| Samuel England | Berenberg |
| Beatrice Allen | Berenberg |